MPOX
JOIN

Moderna COVID-19 Vaccine (mRNA-1273): standardized template with key considerations for a benefit/risk assessment

This paper uses a BRAVATO nucleic acid template to review the features of Moderna’s rapid-response proprietary vaccine platform based on an mRNA delivery system used to develop the Moderna COVID-19 Vaccine (mRNA-1273).

Click here to view the article >

More SAFETY TEMPLATES

Standardized template with key considerations for a benefit/risk assessment for the emergent vesicular stomatitis virus (VSV) viral vector vaccine for Lassa fever

June 2, 2025

Comirnaty COVID-19 mRNA vaccine: standardized template with key considerations for a benefit-risk assessment

August 27, 2024

Novavax COVID-19 Vaccine (NVX-CoV2373), a recombinant spike protein vaccine with Matrix-M adjuvant to prevent disease caused by SARS-CoV-2 viruses

October 26, 2023

Live-attenuated viral vaccines: standardized template for collection of key information for benefit-risk assessment

October 13, 2023

Viral vector vaccines: standardized template for collection of key information for benefit-risk assessment

October 13, 2023

Vaccines based on replication incompetent Ad26 viral vectors: Standardized template with key considerations for a risk/benefit assessment

October 13, 2023
View All

More Safety Templates

Email:
bc-coordinator@taskforce.org

Address:
The Task Force for Global Health,
330 W. Ponce de Leon Ave.
Decatur, GA 30030

Linkedin

© Brighton Collaboration  2023. All rights reserved.